Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019025606) COMPOSITIONS FOR USE FOR TREATING CUTANEOUS LEISHMANIASIS
Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

CLAIMS

A composition comprising dihydroquercetin and alpha-tocopherol for use in the treatment of leishmaniasis.

2. The composition for use according to claim 1, wherein the concentration of dihydroquercetin in the composition ranges from 2% to 8.0% w/w, preferably from 2.5% to 7.0% w/w; and wherein the concentration of alpha-tocopherol in the composition ranges from 0.1% to 3% w/w, preferably from 0.5% to 2% w/w, in weight to the total weight of the composition.

3. The composition for use according to claim 1 or claim 2, further comprising bisabolol.

4. The composition for use according to claim 3, wherein the concentration of bisabolol in the composition ranges from 0.1% to 8.0% w/w, preferably from 2.5% to 4.0% w/w, in weight to the total weight of the composition.

5. The composition for use according to any one of claims 1 to 4, further comprising a compound of formula (I):


wherein: Z represents a halogen atom selected from the group consisting of CI, Br, I and F; and Y represents a substituent selected from a group consisting of C2H5O- , -NH-CO-NH-R in which R represents H, an alkyl or aryl group and N-Rl wherein Rl is an alkyl or heterocyclic group.

The composition for use according to claim 5, wherein the compound of formula (I) is 3-(2-chloroacetamido) ethyl benzoate or 4-(2-chloroacetamido) ethyl benzoate.

7. The composition for use according to claim 5 or claim 6, wherein the concentration of the compound of formula (I) in the composition ranges from 0.05 % to 1.0% w/w, preferably from 0.1% to 0.6% w/w, in weight to the total weight of the composition.

8. The composition for use according to any one of claims 1 to 7, further comprising at least one pharmaceutically and/or cosmetically acceptable vehicle.

9. The composition for use according to claim 8, wherein said at least at least one pharmaceutically and/or cosmetically acceptable vehicle is selected from triglycerides, animal fat, vegetable fat, higher alcohols, glycols, mineral oil, and a mixture thereof.

10. The composition for use according to any one of claims 1 to 9, wherein said composition further comprises at least one component selected from surfactants, pigments, stabilizers, emollients, humectants, perfumes, preservatives, and a mixture thereof.

11. The composition for use according to any one of claims 1 to 10, wherein said composition is a cream, a gel, an ointment, a solution, an emulsion, a mask, a milk, a lotion, a serum, a paste, a stick, a foam or a suspension; preferably a cream or a stick.

12. The composition for use according to any one of claims 1 to 11, wherein the leishmaniasis is visceral leishmaniasis, cutaneous leishmaniasis or mucosal leishmaniasis, preferably the leishmaniasis is cutaneous leishmaniasis.

13. The composition for use according to any one of claims 1 to 11, wherein the parasitic protozoa responsible of leishmaniasis is Leishmania aethiopica, Leishmania amazonensis, Leishmania braziliensis, Leishmania donovani, Leishmania guyanensis, Leishmania infantum, Leishmania lainsoni, Leishmania lindenbergi, Leishmania mexicana, Leishmania major, Leishmania naijfi,

Leishmania panamensis, Leishmania peruviana, Leishmania shawi, Leishmania tropica and/or Leishmania venezuelensis; preferably Leishmania amazonensis, Leishmania donovani, Leishmania mexicana and/or Leishmania major.

A pharmaceutical and/or cosmetic composition for use in the treatment of leishmaniasis, said pharmaceutical and/or cosmetic composition comprising a composition as described in any one of claims 1 to 11.

15. A device, preferably a delivery device, for use in the treatment of leishmaniasis, said device comprising a composition as described in any one of claims 1 to 11.